New injection for seasonal allergies in teens
Treatments studied
Part of Ear, nose & throat, Immune system & allergy, Lungs & breathing clinical trials.
This trial tests a new biologic medicine (injection) to see if it can better control seasonal allergy symptoms in teens who haven't had good relief from standard treatments like nasal sprays.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 17 years old.
- You have had seasonal allergies for at least 2 years.
- You weigh at least 40 kg (about 88 pounds).
- Your allergy symptoms have been hard to control with nasal steroid sprays or other allergy medicines.
- You have not had a biologic injection (like Xolair) for allergies or asthma in the last 10 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an injectable medication called Stapokibart for teenagers with seasonal allergies (hay fever). It aims to see if the drug can reduce allergy symptoms like sneezing, runny nose, and itchy eyes.
This trial tests whether PL-14, a new nasal spray, works better than saline spray at relieving seasonal allergy symptoms like sneezing, itching, and congestion. If it works well and is safe, it could offer patients a new way to manage allergies during pollen season.
This study tests a new nasal spray (ALDP001) in adults with seasonal allergies to ragweed. It aims to find the best dose and how often to use it.
This study looks at how well an allergy injection called Stapokibart works for people with seasonal allergic rhinitis (hay fever). If you qualify, you'll receive the treatment as part of your normal care, and the study team will track your results.
This study tests a new injection called MG-K10 for people with moderate-to-severe seasonal hay fever that isn't well controlled by standard treatments like nasal sprays or antihistamines. The goal is to see if it can reduce your allergy symptoms over the pollen season.
This study tests a new medicine called Stapokibart for children aged 2 to 11 with moderate-to-severe atopic dermatitis (also called eczema) that hasn't improved with topical creams. The medicine is given as an injection and may help reduce itching and skin symptoms.
Hear when a new Seasonal Allergic Rhinitis (SAR) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.